Exhibit 99.3
STRYKER CORPORATION
Transcript of a conference call for financial analysts held at 8:00 AM ET on November 4, 2019 regarding the announcement of a definitive agreement to acquire Wright Medical
Corporate Participants
Glenn S. Boehnlein Stryker Corporation — VP & CFO
Katherine A. Owen Stryker Corporation — VP of Strategy & IR
Kevin A. Lobo Stryker Corporation — Chairman & CEO
Spencer S. Stiles Stryker Corporation — Group President of Orthopaedics & Spine
Conference Call Participants
Craig William Bijou Cantor Fitzgerald & Co., Research Division — Research Analyst
David Ryan Lewis Morgan Stanley, Research Division — MD
Frederick Allen Wise Stifel, Nicolaus & Company, Incorporated, Research Division — MD & Senior Equity Research Analyst
Hima B. InguvaBofA Merrill Lynch, Research Division — Director
Jeffrey D. Johnson Robert W. Baird & Co. Incorporated, Research Division — Senior Research Analyst
Kyle William Rose Canaccord Genuity Corp., Research Division — Senior Analyst
Lawrence H. Biegelsen Wells Fargo Securities, LLC, Research Division — Senior Analyst
Matthew Oliver O’Brien Piper Jaffray Companies, Research Division — MD and Senior Research Analyst
Matthew Stephan Miksic Crédit Suisse AG, Research Division — Senior Research Analyst
Rajbir Singh Denhoy Jefferies LLC, Research Division — MD, Equity Research & Senior Equity Research Analyst
Richard S. Newitter SVB Leerink LLC, Research Division — MD of Medical Supplies & Devices and Senior Research Analyst
Robert Adam Hopkins BofA Merrill Lynch, Research Division — MD of Equity Research
Robert Justin Marcus JP Morgan Chase & Co, Research Division — Analyst
Vijay Muniyappa Kumar Evercore ISI Institutional Equities, Research Division — MD
Presentation
Operator
Welcome to today’s conference call. My name is Jessa, and I will be your operator for today’s call. (Operator Instructions) This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking information, factors that could cause actual results to differ materially are discussed in the company’s most recent filings with the SEC. Also, the discussions will include certainnon-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today’s press release that is an exhibit of Stryker’s current report on Form8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir.
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
Good morning, and thank you for joining the call today to discuss our agreement to acquire Wright Medical. Joining me on today’s call is Spencer Stiles, Group President, Orthopaedics and Spine; Glenn Boehnlein, our CFO; and Katherine Owen, VP of Strategy and Investor Relations.
I will make some opening comments before turning the call to Spencer, who’ll walk through the strategy rationale in more detail. Glenn will then cover the transaction details before opening the call to Q&A.
Please note that we have included a PowerPoint presentation, with the slides available on our website.
Today’s announcement is aligned with Stryker’s mission, which is shown on Slide 3, and has been shared with you many times before. Our mission is that, together with our customers, we are driven to make health care better. With Wright Medical as part of our company, we will be better positioned to serve both surgeons and patients in the Trauma and Extremities market.
Slide 4 shows our corporate strategy, which illustrates our long-held goal of pursuing category leadership in the areas of med tech where we operate. This acquisition clearly fits with this strategy and each of its pillars.
Turning to Slide 5. With Wright Medical, Stryker will be a leading player in the fast-growing $5 billion extremities markets. Importantly, this deal provides Stryker with a global presence, powered by 2 complementary world-class selling organization. As we look at Wright Medical’s comprehensive and highly competitive portfolio, Stryker will meaningfully bolster its ability to compete and innovate in the nearly $2 billion global shoulder market, where we have been subscale for years. When we unite, we will have leading offerings in upper and lower extremities and Biologics that will enhance our capabilities in the orthopedic market. We also expect to be able to achieve meaningful synergies given our highly complementary sales mix.
Looking at Slide 6, we have built a strong M&A capability over the years, with extensive experience in identifying, acquiring, integrating and optimizing targets that help drive category leadership. We expect to continue to pursue deals going forward that are consistent with our history of mostlytop-end transactions.
Finally, I would like to complement Bob Palmisano and the Wright medical leadership team for building a strong company with a compatible culture focused on customer specialization product quality and compliance. These attributes were critical to our conviction in both the strategic rationale of this deal and our ability to drive the successful integration that will create shareholder value.
I will now turn the call over to Spencer.
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
Thanks, Kevin. I would also like to express my gratitude to both the Wright Medical and Stryker leadership teams for the incredible effort to put forth to bring together these highly complementary players in the fast-growing extremities market.
As outlined on Slide 7, at Stryker, we are driven to make health care better, through the product and services we offer that help our customers rebuild lives. This is a common goal that unites our organization, including our people, customers and ultimately, their patients. We believe the addition of Wright Medical will better position Stryker to deliver on our mission.
Turning to Slide 8, and as Kevin stated, Stryker has long been focused on achieving category leadership in this attractive and strategically important segment of the global orthopedics market. A key value driver for this acquisition is Wright Medical’s impressive selling organization, which is aligned with Stryker’s focus on investing in specialty sales forces. Customer specialization is a long-held competitive advantage at Stryker, which we believe uniquely positions us to compete effectively. With this deal, Stryker will have a combined global sales team with a significant presence in all areas of the fast-growing and innovative extremities market. As we have met with many of you over the years at various investor events, a common theme for Stryker has been our belief in our ability to consistently deliver organic sales growth at the high end of med tech. This belief requires achieving category leadership in the segments in which we operate and the markets we compete in.
2
Turning now to Slide 9. As we bring Wright Medical into Stryker, we will be a category leader in all segments of the $5 billion extremity markets on a global basis, including foot and ankle, upper extremities and Biologics. While we are pleased with the improved momentum we have seen in our own extremities business, this transaction will give us the ability to establish a differentiated and global presence. With Wright Medical, we have abest-in-class portfolio, supported by a highly complementary selling organization, allowing for immediate presence in key OUS geographies. The addition of Wright Medical shoulder offering will significantly enhance our ability to compete and innovate in this important and fast-growing market. And through our due diligence, we’ve become increasingly excited about Wright Medical’s Blueprint technology, a unique and strong enabling technology that offers meaningful competitive advantages.
As outlined on Slide 10, BLUEPRINT’s automated surgeon-controlled software allows 3D construction in real-time planning access, along with a number of additional benefits. Longer term, BLUEPRINT will enable outcomes tracking and analytics to further enhance the surgeon’s ability to impact the continuum of care and improve patient outcomes. And along with shoulder BLUEPRINT, Wright Medical’s portfolio fills additional gaps, such as elbow replacement, radial head repair and other differentiated foot and ankle technologies.
Overall, we are excited about the opportunity to bring Wright Medical into our Trauma and Extremities orthopedics team to significantly increase the competitiveness of our extremities and Biologics offering. We believe our extensive experience in M&A positions us well to execute the integration and achieve meaningful synergies and scope. As a company with a long history of investing in specialized sales force talent, we look forward to achievingbest-in-class performance through a combined sales force, a comprehensive market-leading product portfolio and an exciting pipeline to ensure we continue to gain market share.
With that, I will now turn the call over to Glenn.
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Thanks, Spencer. As detailed in today’s press release and summarized on Slide 11, we have reached a definitive agreement to acquire all the issued and outstanding common shares of Wright Medical for $30.75 per share, or a total equity value of approximately $4 billion and an enterprise value of approximately $5.4 billion, which includes the convertible notes. Under the terms of the agreement, Stryker will commence a tender offer for all outstanding common shares of Wright Medical for $30.75 per share in cash. The boards of directors of both Stryker and Wright Medical have approved the transaction. The closing of the transaction is subject to receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an extraordinary General Meeting of Wright Medical shareholders, completion of the tender offer and other customary closing conditions. The acquisition of Wright Medical is expected to close in the second half of 2020. Assuming a Q3 2020 closing, we expect the transaction to be neutral to 2020 adjusted earnings with 10% — $0.10 of dilution in 2021 and accretive thereafter. We continue to target a minimum of 9% adjusted earnings growth in 2020 and beyond. We will likely not deliver our 30 to 50 basis points of op margin expansion in 2020 or 2021, given the high level of dilution, but we will continue to drive underlying op margin expansion, and we’ll share our results with and without the transaction dilution.
We expect ROIC to be greater than 7% by the end of year 5. This assumes cost synergies of $100 million to $125 million, most of which are achieved in the first 3 years, post-closing.
With that, we will now open the call to Q&A.
Questions and Answers
Operator
(Operator Instructions) Your first question comes from the line of Bob Hopkins from Bank of America.
Robert Adam Hopkins — BofA Merrill Lynch, Research Division — MD of Equity Research
Just 2 quick questions. The first one is, I guess, both of them are really on some of the guidance that you guys provided. I’m just curious with the accretion dilution guidance that you provided, what sort of divestitures have been contemplated in there? And maybe you could just talk about the potential for divestitures to be needed to complete this transaction?
3
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes. Thanks, Bob. I think right now, it’s premature to get into details around what, if any, divestitures may occur. We’re going to go through this process. We obviously did extensive due diligence and got very comfortable with what the combined entity would look like. But at this point, given how early it is, we’re not going to discuss any potential divestitures?
Robert Adam Hopkins — BofA Merrill Lynch, Research Division — MD of Equity Research
Okay. But — so the $0.10 that you talked about, does not assume any divestitures, then, I guess?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
I think the way we look at it and how we’ve modeled it, we feel very comfortable with the combined portfolio.
Robert Adam Hopkins — BofA Merrill Lynch, Research Division — MD of Equity Research
Okay. And then just my question — my other question is just on the revenue growth assumptions that you’re making for the asset you’re acquiring going forward. Just maybe talk about your confidence in the sustainability of the market growth rates that we’re seeing today in shoulders? And what specifically you assume for kind of the revenue growth outlook for this asset in your accretion dilution targets that you outlined?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
Bob, this is Spencer. I’ll share a few remarks. Obviously, we’re not going to give exact revenue guidance on the future. However, we feel very confident in these markets. They’re both high single-digit growers, upper extremity and lower extremity, accretive to overall Stryker’s organic growth, and we remain confident in the future of the needs in the market and continued growth, both, I would say, short- and midterm. And longer term, plenty of opportunity for innovation and additional patient access in these spaces.
Operator
Your next question comes from the line of David Lewis from Morgan Stanley.
David Ryan Lewis — Morgan Stanley, Research Division — MD
Just a couple for me. I guess the first question, Spencer, for you is, obviously, Wright struggled of late with both sales attrition as well as their Cartiva product. I guess, how did you think about the risk and opportunities associated with those 2 things? On one hand, obviously, Wright is trading at a lower price because of these issues. On the same hand, they may create some integration-related issues. So how did you get comfortable with the recent dynamics going on at Wright Medical?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
Yes. Cartiva, it remains a great technology for the Wright patients. And we believe in the long-term clinical viability of Cartiva and remain excited about that technology. I think it is publicly shared that they had some disruption in their selling organization related to those integration challenges and that has now been sorted out. It is combined in their direct selling organization for lower extremities, and we remain excited in this technology space for the Wright patients over time.
4
David Ryan Lewis — Morgan Stanley, Research Division — MD
Okay. And just Kevin or Spencer, two quickfollow-ups. One is, just as it relates to sales integration, Kevin, can you help investors understand, spine historical integration issues relative to extremities. Obviously, Wright and Tornier struggles with some extremities — some integration-related issues. So how you’re thinking about the integration across the Stryker portfolio? And then robotics, you mentioned BLUEPRINT. You’v been relatively mum on your robotic initiatives in the non-recon large joint. Where are you? And is that a significant driver of this transaction?
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
Yes. First, I’d tell you, sales force and sales force specialization is a hallmark of Stryker’s success. So we really know how to run sales force as we have models that are both direct and indirect using sales agents, and we believe we’re going to be able to bring that to bear. In spine, currently, we took a little bit of a step back, which we talked about last week on the earnings call, but still, are expected to grow year-over-year, which is differentiated from other spine deals. And as it relates to enabling technologies, we really are big believers that there’s room for navigation, there’s room for guides and robotics, that all have a room to play. You even saw with our recent Mobius acquisition, imaging has a role to play. So we’re a big believer in all forms of enabling technologies.
Operator
Your next question comes from the line of Robbie Marcus from JPMorgan.
Robert Justin Marcus — JP Morgan Chase & Co, Research Division — Analyst
Great. I was wondering how this deal impacts your M&A strategy going forward? Does this still leave you the opportunity to do continued deals here? Or is this set for the foreseeable future?
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
So with this deal, we still have the capacity to continue to dotuck-in deals even as we delever following the acquisition.
Robert Justin Marcus — JP Morgan Chase & Co, Research Division — Analyst
And now with this deal, and assume it will be complete later next year, are there any other gaps in this orthopedic portfolio that you see standing out? Or any other areas that you think need to be filled up here following this acquisition?
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
We’re really excited about the portfolio expansion this provides in our upper extremities portfolio and our lower extremities portfolio and Biologics. There’s always opportunity for growth as new innovation comes to the market, we’ll continue to assess those opportunities. But the combined portfolios are robust and excited — and we’re excited about how that plays into the future of this business.
Operator
Your next question comes from the line of Rick Wise from Stifel.
Frederick Allen Wise — Stifel, Nicolaus & Company, Incorporated, Research Division — MD & Senior Equity Research Analyst
I just wanted tofollow-up. I assume this was not a competitive process and that there’s not ago-shop period, Kevin?
5
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes, I’ll grab that, Rick. We’re probably not going to comment at this point in time regarding whether or not there’s a competitive process. There is a breakup fee payable to us in case another competitor comes in.
Frederick Allen Wise — Stifel, Nicolaus & Company, Incorporated, Research Division — MD & Senior Equity Research Analyst
Yes. And just as a separatefollow-up, I know you’ve commented, but I just wanted to make sure I understood. Does this potentially — well, talk about what this means, more specifically for Mako and extremities? Does this — could this actually accelerate your entry into extremity robotics?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
I think we continue to assess all the technologies, as I mentioned in my remarks, we’re really excited about BLUEPRINT. That particular planning software and future analytics is a differentiated enabling technology. And as we think about our robotics technologies of the future, I think there’ll be a variety of specialties we continue to explore and build out. Too premature to comment on any true road maps for that technology right now as the focus remains still in our drug replacement business, but these enabling technologies playing a really important role in the future of surrounding the entire procedure with enabling technologies.
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
Yes. I think we have said in the past that we are working on both the spine and shoulder as to the next two markets beyond joint replacement that we’re looking at. That hasn’t changed with this acquisition, and we really believe that there’s going to be room for different types of enabling technologies that we’ll be able to be successful in multiple sites of care.
Operator
Your next question comes from the line of Matt Miksic from Crédit Suisse.
Matthew Stephan Miksic — Crédit Suisse AG, Research Division — Senior Research Analyst
Just one. Maybe just on the final decision here to go ahead with a deal like this, I think, in the past, Stryker has looked at lower extremities and sort of maybe contemplated something like this and it went off and sort of built a pretty great lower extremities business on your own, you did an acquisition there and started building your own shoulder, and have been commercializing that, I guess. What, at this stage, really lit this up as the right next step to build out that business, if you could? And then I have onefollow-up.
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
Yes. So we’ve been looking at Wright Medical for a long time, and we really believe now is a good time because they’ve demonstrated their ability to sustain innovation and high growth in all 3 of the segments, be it upper extremities be at lower extremities and Biologics, obviously, with their AUGMENT product, which has come to the market and has been very successful. So there’s sustainability, and honestly, the faster category leadership for us is just going to take a lot longer. And we came to that realization. Obviously, we did a great job on the lower extremities area, not so much on the upper. As you know, we actually are not selling shoulder products outside the United States based on some regulatory challenges. And so — and even in the United States, we have a very, very low market share. So this is one of those where we could really be front of trajectory, and really, they’re the ones that have demonstrated to us over time the sustainability of their business. They’ve done a terrific job in not only delivering on today’s results, but also launching new products, steady cadence of new products. So we’re excited about their capabilities beyond just the sales force, even in terms of their R&D and marketing organizations.
6
Matthew Stephan Miksic — Crédit Suisse AG, Research Division — Senior Research Analyst
That’s great. And thefollow-up, just on the cost synergies. I think this is — there’s a fixed cost aspect of the current Wright Medical business. There’s a cost structure that they have been, I think, doing a good job of working down and driving leverage. If you could highlight maybe 1 or 2 areas where you really feel like sort of theback-end synergies or the whatever the synergies are, quality or shared services, or what do you see as the biggest opportunities there to drive that target that you mentioned?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Sure. Thanks, Matt. I think as we look at Wright Medical, the cost structure. We obviously see areas where there are, first of all, lots of overlap in just general corporate costs that we believe — obviously, we can assume that we could take those out pretty quickly. And then also, if you look at our own sort of cost journey with our CTG program, we feel like we have set up a lot of scalable structures now, especially in our G&A areas, where we’ll be able to move Wright Medical into those and feel fairly confident about achieving the $100 million to $125 million in cost synergies that we referenced.
Operator
Your next question comes from the line of Rajbir Denhoy from Jefferies.
Rajbir Singh Denhoy — Jefferies LLC, Research Division — MD, Equity Research & Senior Equity Research Analyst
Maybe, Spencer, I could ask you about your — kind of your current thoughts on sort of the competitiveness in the lower extremity platform? I mean, as I’m sure you’re aware of what happened. One of the things that happened right last quarter which is losing some sales people in lower extremities. And so now as you’re combining these 2 companies, how do you prevent that from happening further, given the uncertainty now that this introduces into the business?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
Sure. A couple of comments. One, I think this does allow us to compete more effectively over time and innovate against some of the big players in this space, such as Zimmer BioMet and Johnson & Johnson Synthes and does put us on a pathway to #1 in Trauma and Extremities, making this a very attractive place for a sales professional to work. I’d also tell you, through the integration of a variety of other acquisitions we have done, such as K2M, Entellus, NOVADAQ, we continue to be very sensitive about making sure that we prioritize engaging and retaining top sales professionals and talent. So that’s part of our sweet spot at Stryker as we specialize in these selling organizations, ensuring we create a culture and environment that attracts the best and retains the best, and we believe this is the best way to service those specialized customers, be that in upper or lower, and that’s part of the key integration need that we’ll need to execute on in the quarters ahead is to think about how do we ensure that we have thattop-notch selling organizations lined up and ready to go.
Rajbir Singh Denhoy — Jefferies LLC, Research Division — MD, Equity Research & Senior Equity Research Analyst
That’s helpful. And maybe just a clarification for Katherine. So just so we’re clear, the deal model you put together here in the accretion dilution does not assume any divestitures in the business?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
I’ll tell you, we’re not going to comment at this point. I just think it’s premature. When we looked at the target, we did our analysis. We feel very comfortable around the combined entity going forward. What, if any, divestitures, it’s just too early to comment on that.
7
Operator
Your next question comes from the line of Vijay Kumar from Evercore ISI.
Vijay Muniyappa Kumar — Evercore ISI Institutional Equities, Research Division — MD
So maybe, Glenn, on — one on in the deal financing, what kind of assumptions are you making on, because it looks like, just based on some of the numbers you’re putting out. This is all the coming deal debt phase and no cash on hand?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Actually, the transaction will be financed with a combination of newly issued debt and some available cash that we have on the balance sheet.
Vijay Muniyappa Kumar — Evercore ISI Institutional Equities, Research Division — MD
Okay. And then one on margins, I think, you mentioned 30 to 50 basis points for next year. I’m just curious because I think on the K2M side, things should be improving for you guys for 2020. And you’re assuming that 3Q close on the Wright Medical deal. So does your comment for 2020 being below target range, does that assume anything outside of deals? Maybe on the FX side or anything else we should be aware of?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
No. Honestly, my comments really just speak to this specific deal and the amount of dilution and pressure that will put on op margin. And we will — underneath it all, we will continue to drive op margin expansion on our legacy business, just like we normally do. But initially, as we absorb this deal and the related dilution, we don’t expect that we will have 30 to 50 basis points of op margin expansion in 2020 or 2021. But we will resume that target in 2022.
Vijay Muniyappa Kumar — Evercore ISI Institutional Equities, Research Division — MD
So this does not assume any FY 2020 free cash deployment, correct? On the deal model?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Explain your question again? It doesn’t assume any what?
We lost them. That’s okay. I think his question really related to is there a cash that will be deployed for this deal. So there is a portion of the deal that will be financed through available cash on our balance sheet.
Operator
Your next question comes from the line of Craig Bijou from Cantor Fitzgerald.
Craig William Bijou — Cantor Fitzgerald & Co., Research Division — Research Analyst
I just wanted to see if you could talk a little bit about the overlap, particularly on the lower side, customers, products and maybe any expectations or how we should think about dissynergies that you’ve modeled in?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes, I’ll take part of it. In terms of the portfolio and as many of you know, we’re both well covered public companies. We think, overall, the portfolios are highly complementary. We do have some similar product offerings, but as I said previously, we’re just not going to get into detail around what, if any, possible divestitures may be required. But we do have a highly complementary portfolio in both upper and lower.
8
Craig William Bijou — Cantor Fitzgerald & Co., Research Division — Research Analyst
And then just afollow-up, Katherine, on the diligence that you’ve mentioned a couple of times. I mean, any more color there and why you do feel comfortable from a regulatory perspective?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Going through — we’ve done a lot of acquisitions, as Kevin referenced on the call, and they’ve gotten very comfortable with our process of going through due diligence and analyzing product portfolios. And it was through that process that we got very comfortable regarding what, if any, divestitures may be required.
Operator
Your next question comes from the line of Larry Biegelsen from Wells Fargo.
Lawrence H. Biegelsen — Wells Fargo Securities, LLC, Research Division — Senior Analyst
Just two quick ones for me. One on the size of your extremities business, published reports had it at about $125 million among the $1.6 billion in your Trauma and Extremities line, and it’s at mostly lower extremities? And just lastly, a simple one, what happens to the Stryker shoulder portfolio? Are you going to continue to support that?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes. So again, we’re not going to comment on any rationalization that may or may not occur in terms of our portfolio. We’re just announcing the deal today. We have a lot of work to get through to close and integrate, and as I referenced before, we think the portfolios are highly complementary, but it is just premature to start talking about what products we may or may not discontinue going forward.
Lawrence H. Biegelsen — Wells Fargo Securities, LLC, Research Division — Senior Analyst
And is your extremities business, Katherine, about $125 million in that Trauma and Extremities line?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes. We don’t break out to that level of detail in terms of the — when you’re getting into — within the divisions?
Operator
Your next question comes from the line of Matthew O’Brien from Piper Jaffray.
Matthew Oliver O’Brien — Piper Jaffray Companies, Research Division — MD and Senior Research Analyst
I hope you can hear me okay, sorry about the background noise. Just curious about — you’re not wanting to talk much about the divestiture or divestitures you may need to see from this deal, but can you talk a little bit about the synergistic opportunities on the sales side? What can you do with this broader portfolio, especially stemless shoulder going forward, both domestically and internationally?
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
Yes, I think that the first benefit in the upper extremities is to have more specialization. So because of our lack of scale in upper extremities, we only have a very few dedicated upper extremity salespeople. Wright Medical comes with a completely dedicated sales force. And our goal across all of our specialties that we serve is to be as specialized as possible. So this gives us a huge shot in the arm to increase specialization just on the sales force side. Spence, do you want to add?
9
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
I’d build upon just — the portfolios themselves are very complementary, and the upper extremities were extremely excited about the breadth. Obviously, in shoulder, but then in some of the other technologies as well, such as elbow and wrist, and even some of the things that they referenced publicly before, such as their new plating system for shoulder called SPS ORTHOLOC that’s coming out. So this broadens that portfolio in upper extremities. And as Katherine mentioned earlier, very complementary in lower extremities as well. And back to the markets, these are the fastest-growing markets in orthopedics. So we like the breadth and scale this gives us. You combine that with our specialized sales force, and we think there’s great opportunity for continued growth in this space.
Matthew Oliver O’Brien — Piper Jaffray Companies, Research Division — MD and Senior Research Analyst
And just a quickfollow-up, just on AUGMENT, that product has done well, pretty narrow indications at this point. Any thoughts on taking that product to other parts of the body going forward?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
It’s premature to comment on future plans related to expanded indications, but you can imagine diligence, we like what we’ve seen with AUGMENT as well and the success they’ve had with their Biologics portfolio, and this is another great technology to bring into the Stryker portfolio.
Operator
Your next question comes from the line of Richard Newitter from SVB Leerink.
Richard S. Newitter — SVB Leerink LLC, Research Division — MD of Medical Supplies & Devices and Senior Research Analyst
Just hoping you could give us a little bit more color on the timing of both the cost synergies over the3-year period? And where you think the synergies will be the easiest? And what proportion of those you can get in year 1 versus maybe towards the later end? And then two, Katherine, what is the — not necessarily divestiture related, but what is the kind of the dissynergy assumption upfront potentially in 2020 and/or year 1, however you want to describe it?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Okay. Rick, I’ll do the first question. I think, as I mentioned, we’re looking at really primarily cost synergies that are within the SG&A line items of Wright Medical. And as you think about over the 3 years, we obviously are assuming sort of maximum annual synergies of about 15% of Wright Medical’s SG&A. And that ramps from ‘21 to sort of full value in 2023.
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes, in terms of dissynergies, it’s early to get into those details, obviously. When you bring 2 organizations together, there is a period where you have some sales dissynergies as we get closer to close and start thinking about 2021, we can give more detail.
Richard S. Newitter — SVB Leerink LLC, Research Division — MD of Medical Supplies & Devices and Senior Research Analyst
Okay. But just on afollow-up there, Katherine, is it fair to assume that you guys have factored in some level of dissynergy as a placeholder in the beginning?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes.
10
Operator
Your next question comes from the line of Jeff Johnson from Baird.
Jeffrey D. Johnson — Robert W. Baird & Co. Incorporated, Research Division — Senior Research Analyst
Two justfollow-up questions. One, Katherine, I know you don’t want to talk about dissynergies a whole lot and things like that, but presumably, the Q3 ‘20 close, I’m assuming that’s because you would anticipate at least some level of FTC review in some parts of the business?
Katherine A. Owen — Stryker Corporation — VP of Strategy & IR
Yes, that’s correct.
Jeffrey D. Johnson — Robert W. Baird & Co. Incorporated, Research Division — Senior Research Analyst
Okay. And then just on the synergies, I guess, just to push you a little bit more there on the $100 million to $125 million. If I look at Wright Medical’s P&L, that would take their OpEx, excluding amortization and those kind of things f maybe 75% to 60%, you guys closer to 60% — you guys closer to 40%, industry standard, probably closer to that 40% as well. Why not be able to get closer to your level of OpEx sooner than what’s anticipated in that $100 million to $125 million in synergies?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Sure. I think a couple of things you have to consider. First of all, Wright Medical is a very fast-growing company, and we would want to make sure that we don’t change that outlook for them. And secondly, these things take time, and obviously, integrating 2 large organizations like this has a lot of complexity. So right now, we’re very comfortable with $100 million to $125 million, reaching sort of maximum velocity by year 3.
Operator
Your next question comes from the line of Hima Inguva from Bank of America.
Hima B. Inguva — BofA Merrill Lynch, Research Division — Director
Great. Beyond recognizing you have managed the balance sheet conservatively over the years, hoping, if you could share a few specifics getting some investor calls this morning: one, split between debt and cash that will be used to finance the deal; two, the delevering plan from this deal and commitment you had in tradings; and then three, how are you thinking about the balance sheet going forward in the longer term, please?
Glenn S. Boehnlein — Stryker Corporation — VP & CFO
Sure. At this time, I really don’t want to get into sort of the mix between debt and cash. Obviously, there will be a majority of newly issued debt and some available cash that we’ll use for the deal. In terms of deleveraging, we see that ourdebt-to-adjusted-EBITDA will probably peak at 3.0 in 2020, and then we’ll have a plan to bring that down, and we’re actively in discussions with the credit rating agencies for that to share that plan with them. And then lastly, on the balance sheet, we will continue to drive sort of our balance sheet metrics that we traditionally do, and part of that will be delevering from this plan, but also working on sort of our underlying balance sheet metrics to improve cash flow.
Operator
Your next question comes from the line of Kyle Rose from Canaccord.
11
Kyle William Rose — Canaccord Genuity Corp., Research Division — Senior Analyst
I just wanted to ask one product related. When you look at Wright, specifically on their BLUEPRINT 3D planning portfolio there. How do you view that as a potential driver for the broader total joint recon? And correct me if I’m wrong, but I don’t believe you have a PSI portfolio now, how do you view this as an asset that drives just the broader recon portfolio on ago-forward basis?
Spencer S. Stiles — Stryker Corporation — Group President of Orthopaedics & Spine
This is Spence. We’re not going to speculate on product introductions for the future. But in diligence, we were very impressed with BLUEPRINT and its capabilities in upper extremity, where it’s primarily utilized today in some of the pipeline of investments that they have been making into the upper extremity business related to their enabling technology. As I mentioned earlier, we’re excited about what this technology could offer, but we have to get in a diligence and further understand the investments needed, the roadmaps and the times. It is a software-based technology, so making sure we have the right talent and the right thought process around product introductions there. But as of right now, we’re not speculating on additional product releases related to BLUEPRINT.
Operator
There are no further questions at this time I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.
Kevin A. Lobo — Stryker Corporation — Chairman & CEO
So thank you all for joining today’s call. As you have heard, we are tremendously excited about the opportunity to bring Wright Medical into Stryker and achieve category leadership in this important fast-growing segment of the orthopedic industry. Thank you.
Operator
Thank you. Ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.
Disclaimer
THE INFORMATION CONTAINED IN THIS TRANSCRIPT IS A TEXTUAL REPRESENTATION OF THE CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS TRANSCRIPT. INVESTORS ARE ADVISED TO REVIEW THE COMPANY’S CONFERENCE CALL ITSELF AND THE COMPANY’S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
Forward-looking statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the failure to satisfy any of the closing conditions to the acquisition of Wright, including the receipt of any required regulatory clearances (and the risk that such clearances may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); delays in consummating the acquisition of Wright; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the proposed Wright transaction (or the announcement thereof) on the parties relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes
12
in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form10-K and Quarterly Reports on Form10-Q.
Additional Information and Where to Find It
The tender offer for Wright’s outstanding ordinary shares referenced herein has not yet commenced. This communication is not a recommendation, an offer to purchase or a solicitation of an offer to sell ordinary shares of Wright or any other securities. This communication may be deemed to be solicitation material in respect of the EGM Proposals (defined below). At the time the tender offer is commenced, Stryker will file with the Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO, and Wright will file with the SEC a Solicitation/Recommendation Statement on Schedule14D-9. Wright also intends to file with the SEC a proxy statement in connection with an extraordinary general meeting of shareholders of Wright, at which the Wright shareholders will vote on certain proposed resolutions (the “EGM Proposals”) in connection with the transactions referenced herein, and will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting. SHAREHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE14D-9 AND THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO ANY OF THE FOREGOING) WHEN SUCH DOCUMENTS BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION THAT PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES OR MAKING ANY VOTING DECISION. Shareholders can obtain these documents when they are filed and become available free of charge from the SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by Stryker will be available free of charge on Stryker’s website, www.stryker.com, or by contacting Stryker’s investor relations department at katherine.owen@stryker.com. Copies of the documents filed with the SEC by Wright will be available free of charge on Wright’s website, www.wright.com, or by contacting Wright’s investor relations department at julie.dewey@wright.com. In addition, Wright shareholders may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement on Schedule TO.
Participants in the Solicitation
Wright, its directors and executive officers and other members of its management and employees, as well as Stryker and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from Wright’s shareholders in connection with the EGM Proposals. Information about Wright’s directors and executive officers and their ownership of Wright ordinary shares is set forth in the proxy statement for Wright’s 2019 annual general meeting of shareholders, which was filed with the SEC on May 17, 2019. Information about Stryker’s directors and executive officers is set forth in the proxy statement for Stryker’s 2019 annual meeting of shareholders, which was filed with the SEC on March 20, 2019. Shareholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the EGM Proposals, including the interests of Wright’s directors and executive officers in the transaction, which may be different than those of Wright’s shareholders generally, by reading the proxy statement and other relevant documents regarding the transaction which will be filed with the SEC.
13
